Loading...

MIRA MIRA PHARMACEUTICALS INC US FDA Inspections 8-K Filing

MR P

MR

MIRA PHARMACEUTICALS INC

(MIRA)

2025 8-K

Show Summary

Summary

Clinical Trials

Clinical Trials

Equity Offerings

Asset Acquisitions

Asset Acquisitions

Asset Acquisitions

Clinical Trials

Product Expansion

Positive Study Results

Clinical Trial Launch

Acquisition Agreement

Product Development

Clinical Trial Approval

Accounting Firm Change

Drug Safety Validation

Management Changes

Clinical Trial Announcement

Ketamir-2 Efficacy

Ketamine Study Results

Annual Meeting Results

Drug Development Update

Preclinical Success

Compliance Regained

Preclinical Study Data on K...

Preclinical Success

Delisting Notice

Changes in Management

Board Restructuring and Res...

Discovery of New Molecule

Resignation of Director

Appointment and Resignation

License Agreement and Loan ...

Appointment and Resignation...

Amendment to Employment Agr...

Public Offering

External Links:

MIRA Pharmaceuticals, Inc. announced that the FDA cleared its IND application for Ketamir-2, enabling U.S. clinical trials for a non-opioid treatment of neuropathic pain, with plans to launch Phase 2a by the end of 2025. This announcement also included data showing Ketamir-2's superior efficacy to gabapentin and pregabalin in preclinical trials.

AI Assistant

MIRA PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.